Aldeyra Therapeutics, Inc. (ALDX) stock
ALDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.67+0.03 (+4.01%)
Close on Nov 16, 2026Market cap $40.39MP/E –Yield –
Aldeyra Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Aldeyra Therapeutics's total debt was $0 at Jun 30, 2026. For fiscal 2025 it was $15.25M, up 1.5% from the year before. Over ten years it grew 28.4% a year on average. The highest annual figure on record is $15.83M in fiscal 2022.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.25M | +1.5% |
| FY2024 | Dec 31, 2024 | $15.03M | -0.8% |
| FY2023 | Dec 31, 2023 | $15.15M | -4.3% |
| FY2022 | Dec 31, 2022 | $15.83M | +2.1% |
| FY2021 | Dec 31, 2021 | $15.50M | +35.6% |
| FY2020 | Dec 31, 2020 | $11.43M | -21.3% |
| FY2019 | Dec 31, 2019 | $14.53M | +987.0% |
| FY2017 | Dec 31, 2017 | $1.34M | +1.5% |
| FY2016 | Dec 31, 2016 | $1.32M | +2.1% |
| FY2015 | Dec 31, 2015 | $1.29M | +2.9% |
| FY2014 | Dec 31, 2014 | $1.25M | +5.5% |
| FY2013 | Dec 31, 2013 | $1.19M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | -100.0% |
| Q1 FY2026 | Mar 31, 2026 | $15.30M | +1.3% |
| Q4 FY2025 | Dec 31, 2025 | $15.25M | +1.5% |
| Q3 FY2025 | Sep 30, 2025 | $15.20M | -0.5% |
| Q2 FY2025 | Jun 30, 2025 | $15.15M | -0.6% |
| Q1 FY2025 | Mar 31, 2025 | $15.10M | -0.7% |
| Q4 FY2024 | Dec 31, 2024 | $15.03M | -0.8% |
| Q3 FY2024 | Sep 30, 2024 | $15.28M | -5.2% |
| Q2 FY2024 | Jun 30, 2024 | $15.24M | -4.9% |
| Q1 FY2024 | Mar 31, 2024 | $15.20M | -4.5% |
| Q4 FY2023 | Dec 31, 2023 | $15.15M | -4.3% |
| Q3 FY2023 | Sep 30, 2023 | $16.12M | +388.0% |
| Q2 FY2023 | Jun 30, 2023 | $16.02M | +49.1% |
| Q1 FY2023 | Mar 31, 2023 | $15.92M | +2.2% |
| Q4 FY2022 | Dec 31, 2022 | $15.83M | +2.1% |
| Q3 FY2022 | Sep 30, 2022 | $3.30M | -78.6% |
| Q2 FY2022 | Jun 30, 2022 | $10.74M | -30.0% |
| Q1 FY2022 | Mar 31, 2022 | $15.59M | +53.7% |
| Q4 FY2021 | Dec 31, 2021 | $15.50M | +35.6% |
| Q3 FY2021 | Sep 30, 2021 | $15.42M | +21.5% |
| Q2 FY2021 | Jun 30, 2021 | $15.34M | +10.2% |
| Q1 FY2021 | Mar 31, 2021 | $10.14M | -30.9% |
| Q4 FY2020 | Dec 31, 2020 | $11.43M | -21.3% |
| Q3 FY2020 | Sep 30, 2020 | $12.69M | -11.8% |
| Q2 FY2020 | Jun 30, 2020 | $13.92M | +932.3% |
| Q1 FY2020 | Mar 31, 2020 | $14.67M | +991.3% |
| Q4 FY2019 | Dec 31, 2019 | $14.53M | +987.0% |
| Q3 FY2019 | Sep 30, 2019 | $14.39M | +980.3% |
| Q3 FY2018 | Sep 30, 2018 | $1.35M | +1.6% |
| Q2 FY2018 | Jun 30, 2018 | $1.34M | +1.7% |
| Q4 FY2017 | Dec 31, 2017 | $1.34M | +1.5% |
| Q3 FY2017 | Sep 30, 2017 | $1.33M | +1.7% |
| Q2 FY2017 | Jun 30, 2017 | $1.33M | +1.8% |
| Q1 FY2017 | Mar 31, 2017 | $1.32M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.32M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.31M | – |
| Q2 FY2016 | Jun 30, 2016 | $1.30M | – |
See a number that looks wrong?